載入中
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
前收盤價
US$8.33
+US$0.32 · +4.00%
盤中時間採用ET。市場資料可能有所延遲。
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
日內區間
目前US$8.33
52週區間
目前US$8.33
盤中時間採用ET。市場資料可能有所延遲。
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
日內區間
目前US$8.33
52週區間
目前US$8.33
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 2461.4萬 USD | 1905.7萬 USD | 1311萬 USD | 783.9萬 USD | 876.5萬 USD |
| 銷售、一般及管理費用 | 978.3萬 USD | 762.4萬 USD | 815.7萬 USD | 616.2萬 USD | 488.1萬 USD |
| 營業費用 | 3439.7萬 USD | 2668.1萬 USD | 2126.7萬 USD | 1400.1萬 USD | 1364.6萬 USD |
| 利息收入 | — | 230.1萬 USD | — | — | — |
| 折舊和攤銷 | 4.3萬 USD | 3.9萬 USD | 3萬 USD | 2.5萬 USD | 2.4萬 USD |
| 營業利益 | −3439.7萬 USD | −2668.1萬 USD | −2126.7萬 USD | −1400.1萬 USD | −1364.6萬 USD |
| 淨利 | −3276.6萬 USD | −2444.4萬 USD | −1938.1萬 USD | −1367.6萬 USD | −1359.2萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$8.33
上漲空間 0.00%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2018年11月15日 | 1:20 | — | — |
已生效 2018年11月15日
1:20
報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM763.97萬0.01%787.4億 USD0.19%US$278.94+0.49%
iShares Russell 2000 Growth ETFIWO274.6萬0.02%139.17億 USD0.24%US$356.78+0.94%
Vanguard Extended Market ETFVXF228.95萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO133.27萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC91.94萬0.07%13.17億 USD0.60%US$183+0.11%
Vanguard Russell 2000 Growth ETFVTWG25.73萬0.01%17億 USD0.06%US$260.49+0.91%
iShares Russell 2500 ETFSMMD16.08萬0.00%40.62億 USD0.23%US$86.29+0.38%
Global X - Russell 2000 ETFRSSL14.48萬0.01%14.19億 USD0.08%US$109.09+0.21%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDGlobal X - Russell 2000 ETFRSSLAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
